Shell Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Shell Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$311K	Sell	5,750 -2,269	-28%	-$130K	0.03%	402
2025 Q2	$441K	Buy	8,019 +3,060	+62%	+$180K	0.02%	514
2025 Q1	$351K	Buy	4,959 +176	+4%	+$11.8K	0.02%	570
2024 Q4	$314K	Buy	4,783 +2,268	+90%	+$152K	0.01%	652
2024 Q3	$177K	Buy	+2,515	New	+$210K	0.01%	879
2024 Q1	$207K	Sell	2,515 -145	-5%	-$13K	0.01%	803
2023 Q4	$256K	Sell	2,660 -1,187	-31%	-$105K	0.01%	770
2023 Q3	$340K	Buy	3,847 +351	+10%	+$31.2K	0.01%	713
2023 Q2	$303K	Sell	3,496 -7,587	-68%	-$714K	0.01%	779
2023 Q1	$1.08M	Hold	11,083	–	–	0.04%	351
2022 Q4	$1.15M	Sell	11,083 -1,893	-15%	-$178K	0.05%	340
2022 Q3	$1.1M	Sell	12,976 -3,428	-21%	-$305K	0.04%	356
2022 Q2	$1.36M	Sell	16,404 -1,722	-10%	-$137K	0.04%	368
2022 Q1	$1.4M	Sell	18,126 -514	-3%	-$43K	0.03%	400
2021 Q4	$1.65M	Buy	18,640 +2,188	+13%	+$181K	0.03%	405
2021 Q3	$1.27M	Sell	16,452 -13,784	-46%	-$1.09M	0.03%	435
2021 Q2	$2.52M	Buy	30,236 +16,885	+126%	+$1.34M	0.05%	321
2021 Q1	$1.01M	Sell	13,351 -17,129	-56%	-$1.4M	0.02%	536
2020 Q4	$2.67M	Buy	30,480 +21,473	+238%	+$1.7M	0.06%	334
2020 Q3	$685K	Sell	9,007 -227	-2%	-$23K	0.02%	561
2020 Q2	$1.14M	Sell	9,234 -12,270	-57%	-$1.22M	0.03%	417
2020 Q1	$1.82M	Sell	21,504 -500	-2%	-$43.1K	0.05%	320
2019 Q4	$1.86M	Buy	22,004 +4,695	+27%	+$355K	0.04%	385
2019 Q3	$1.17M	Hold	17,309	–	–	0.03%	476
2019 Q2	$1.48M	Sell	17,309 -1,400	-7%	-$120K	0.03%	426
2019 Q1	$1.66M	Buy	18,709 +2,531	+16%	+$235K	0.04%	384
2018 Q4	$1.38M	Sell	16,178 -6,558	-29%	-$624K	0.03%	408
2018 Q3	$2.21M	Sell	22,736 -622	-3%	-$62.1K	0.04%	365
2018 Q2	$2.2M	Buy	23,358 +653	+3%	+$57.2K	0.05%	382
2018 Q1	$1.84M	Sell	22,705 -52	-0.2%	-$4.46K	0.04%	418
2017 Q4	$2.03M	Buy	22,757 +3,042	+15%	+$265K	0.04%	394
2017 Q3	$1.83M	Sell	19,715 -2,317	-11%	-$205K	0.04%	389
2017 Q2	$2M	Sell	22,032 -467	-2%	-$42.5K	0.04%	387
2017 Q1	$1.98M	Sell	22,499 -2,085	-8%	-$185K	0.04%	374
2016 Q4	$2.04M	Sell	24,584 -1,213	-5%	-$104K	0.05%	386
2016 Q3	$2.39M	Sell	25,797 -1,618	-6%	-$152K	0.05%	368
2016 Q2	$2.13M	Buy	27,415 +5,179	+23%	+$440K	0.05%	364
2016 Q1	$1.83M	Buy	22,236 +344	+2%	+$28K	0.04%	398
2015 Q4	$2.29M	Sell	21,892 -6,953	-24%	-$726K	0.05%	342
2015 Q3	$2.08M	Buy	28,845 +909	+3%	+$121K	0.03%	454
2015 Q2	$3.82M	Buy	27,936 +656	+2%	+$81.3K	0.08%	263
2015 Q1	$3.4M	Sell	27,280 -7,514	-22%	-$796K	0.06%	304
2014 Q4	$3.15M	Buy	34,794 +5,949	+21%	+$495K	0.05%	338
2014 Q3	$2.08M	Sell	28,845 -5,509	-16%	-$362K	0.03%	468
2014 Q2	$2.14M	Buy	34,354 +550	+2%	+$33.2K	0.03%	464
2014 Q1	$2.31M	Sell	33,804 -3,720	-10%	-$274K	0.04%	441
2013 Q4	$2.64M	Sell	37,524 -16,162	-30%	-$1.1M	0.04%	389
2013 Q3	$3.88M	Sell	53,686 -4,212	-7%	-$280K	0.07%	287
2013 Q2	$3.23M	Buy	+57,898	New	+$3.61M	0.06%	313

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Shell Asset Management's BMRN Position: Q3 2025 in Review

Shell Asset Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 28% in Q3 2025, selling an estimated $130K and leaving 5,750 shares worth $311K. The position accounts for 0.03% of the portfolio, ranked #402.

Shell Asset Management first reported a position in BMRN in Q2 2013 and has held it in 49 quarters since. The position peaked at $3.88M in Q3 2013. 577 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

Shell Asset Management held 5,750 shares of BioMarin Pharmaceuticals worth $311K as of Q3 2025.
Shell Asset Management sold 2,269 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $130K.
BioMarin Pharmaceuticals made up 0.03% of Shell Asset Management's portfolio in Q3 2025, its #402 holding.
Shell Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
Shell Asset Management's BioMarin Pharmaceuticals position peaked at $3.88M in Q3 2013.
577 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.